“Family means no one gets left behind or forgotten,” actor David Ogden Stiers once said. Those are words the CMTA lives by as we push hard every day to make sure no one in our CMT family gets left behind or forgotten. The goal of our Strategy to Accelerate Research (STAR) is to develop treatments for all types of CMT and the entire CMT family.
Although breakthroughs are often viewed as sudden, dramatic discoveries, they are actually the result of relentless hard work and determination. Here is the latest news on our way to treatments for CMT:
- This update covers the demyelinating forms of CMT–1, X and 4—that affect the protective coating, or “myelin” around those nerves. If you give to support Type 1 or Type 4 research by year’s end, your gift will be matched dollar-for-dollar (up to $350,000) by several families who believe strongly in the CMTA’s strategies for demyelinating CMT.
- Our Type 2 update covers the axonal forms of CMT. Thanks to STAR and the support of two committed Type 2 families who are challenging the community to match $1.5 million in donations, we have set the stage for a number of Type 2 breakthroughs.
The CMTA will need several million dollars to implement the strategies for developing these treatments, so if you or a loved one has Type 1, 2 or 4, we are asking you to help us as we keep reaching for our goals.
With your support and our relentless hard work and determination to bring treatments to you, we can force a breakthrough. Donate today! Do it for our family.
On behalf of the entire CMTA family, you have our sincere gratitude.
Amy Gray, CMTA Chief Executive Officer, and Jeana Sweeney, CMTA Director of Development